Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects

A number of drugs that are used recreationally are now being studied for their use in psychopharmacology. But while the ways in which these drugs are similar or different has been described anecdotally by recreational users, they haven’t been studied in comparison to one another. Dr. Matthias Liechti and his team of researchers recently published a study in the journal Neuropsychopharmacology, in which 28 healthy subjects, men and women, take doses of LSD, MDMA, amphetamines, and a placebo over four different sessions. Dr. Liechti says this blinding is important; in other studies, participants either have taken a drug or a placebo and can tell when they’re taking the drug. But in this case they don’t know which drug they’re taking, which allows the effects of the drugs to be compared against each other. Take a listen to find out more!

Hosted on Acast. See acast.com/privacy for more information.

More from NPP BrainPod

  1. 09:08Spotlighting SHAPERS: Sex hormones associated with psychological and endocrine rolesMar 05, 2024
  2. 09:33Comparable roles for serotonin in rats and humans for computations underlying flexible decision-makingJan 04, 2024
  3. 09:58Integrating public health and translational basic science to address challenges of xylazine adulteration of fentanylOct 16, 2023
  4. 08:29The why, when, where, how, and so what of so-called rapidly acting antidepressantsSep 06, 2023
  5. 09:09AI-based analysis of social media language predicts addiction treatment dropout at 90 daysJun 23, 2023
  6. 09:27Oxytocin effects on amygdala reactivity to angry faces in males and females with ASPDApr 21, 2023
  7. 09:54To dismantle structural racism in science, scientists need to learn how it worksFeb 22, 2023
  8. 09:59Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activityDec 22, 2022
  9. 09:29Sex-dependent risk factors for PTSD: a prospective structural MRI studyNov 01, 2022
  10. 09:47Sex differences in appetitive and reactive aggressionSep 06, 2022